Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00001
|
|||||
| Drug Name |
Fesoterodine fumarate
|
|||||
| Synonyms |
Toviaz (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Overactive bladder disorder [ICD11:GC50.0] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C26H37NO3
|
|||||
| Canonical SMILES |
CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2
|
|||||
| InChI |
InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1
|
|||||
| InChIKey |
DCCSDBARQIPTGU-HSZRJFAPSA-N
|
|||||
| CAS Number |
CAS 286930-03-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 411.6 | Topological Polar Surface Area | 49.8 | ||
| Heavy Atom Count | 30 | Rotatable Bond Count | 11 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
5.5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
114788164
,126633314
,126665680
,126666536
,127713256
,135215466
,137147467
,142600549
,14781939
,151981129
,160682498
,160967872
,164841556
,17194959
,174006830
,175268192
,176485080
,187051776
,210276627
,223666877
,224399961
,226492628
,241054700
,242587777
,252448583
,252552193
,43529928
,51091564
,57371974
,74911026
,99443256
|
|||||
| ChEBI ID |
ChEBI:135920
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Fesoterodine fumarate was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012 Apr 1;29(4):259-73. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.